List of Studies ( Metabolite:beta-Alanyl-L-arginine)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
---|---|---|---|---|---|---|---|
ST001855 | AN003006 | The metabolomic resetting effect of FG4592 in AKI to CKD transition-day 21 (Part 1) | Kidney | Mouse | Kidney disease | Children’s Hospital of Nanjing Medical University | AUC |
ST002775 | AN004517 | Zebrafish Retina Regeneration Metabolomics - 3 Days Post Crush | Eye tissue | Zebrafish | Eye disease | University of Miami | Normalized Concentrations |
ST002444 | AN003981 | Zebrafish Optic Nerve Regeneration Metabolomics - 3 Days Post Crush | Eye tissue | Zebrafish | Eye disease | University of Miami | normalized peak areas |
ST000116 | AN000197 | Comparative metabolomics analysis of the key metabolic nodes in propionic acid synthesis in Propionibacterium acidipropionici | Bacterial cells | Propionibacterium | Jiangnan University | Peak area | |
ST002776 | AN004519 | Zebrafish Optic Nerve Regeneration, Tectum Metabolomics - 3 Days Post Crush | Eye tissue | Zebrafish | Eye disease | University of Miami | Peak Area |
ST002066 | AN003365 | Glutaminase inhibition impairs CD8 T cell activation in STK11/Lkb1 deficient lung cancer | Lung | Mouse | Cancer | The Walter and Eliza Hall Institute of Medical Research | peak height |
ST002412 | AN003931 | Metabolic effects of the protein kinase R | Macrophages | Mouse | Hudson | peak height | |
ST003024 | AN004958 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 1 | Bacterial cells | Bacteria | Monash Institute of Pharmaceutical Sciences | peak height | |
ST003036 | AN004977 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 | Bacterial cells | Pseudomonas aeruginosa | Bacterial infection | Monash Institute of Pharmaceutical Sciences | peak height |
ST000403 | AN000642 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes | Cells | Human | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height | |
ST000539 | AN000818 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) | Cells | Human | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height | |
ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
ST002094 | AN003421 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
ST002107 | AN003446 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |
ST002309 | AN003771 | Targeting malaria parasites with novel derivatives of azithromycin | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |
ST001304 | AN002172 | Multi-omics analysis delineates the distinct functions of sub-cellular acetyl-CoA pools in Toxoplasma gondii | Fibroblast cells | Toxoplasma gondii | Parasitic infection | Monash University | Signal Intensity |
ST001315 | AN002189 | Retargeting azithromycin-like compounds as antimalarials with dual modality | Blood | Plasmodium falciparum | Malaria | Monash University | Signal Intensity |